Key Highlights

  • Adherium (ASX:ADR) shares last traded at $0.10 as the company announced a change in Chief Executive Officer.
  • CEO Dawn Bitz is stepping down for personal reasons after leading the company through a period of commercial progress.
  • Chief Commercial Officer John Perry has been appointed Interim CEO with immediate effect to provide leadership continuity.
  • The company said it will continue executing its growth strategy across connected respiratory care, Remote Patient Monitoring and Value Based Care initiatives.

Leadership Transition Announcement

Adherium Limited (ASX:ADR), a digital respiratory management company and developer of the FDA-cleared Hailie Smartinhaler platform, announced on 29 July 2026 that Chief Executive Officer Dawn Bitz has decided to step down from her role for personal reasons. Shares in the Melbourne-based company last traded at $0.10, with the announcement made as part of a broader update on the company's leadership and growth initiatives.

In her place, Adherium's Chief Commercial Officer, John Perry, has been appointed Interim Chief Executive Officer with immediate effect. The company said the appointment is intended to provide leadership continuity as it continues to advance its Remote Patient Monitoring and Value Based Care growth initiatives.

Board and Outgoing CEO Commentary

Adherium's Non-Executive Chair, George Baran, thanked Ms Bitz for her contribution to the company over the past 12 months, crediting her with establishing the company's Remote Patient Monitoring channel, growing recurring Hailie revenues, and positioning Adherium to access Value Based Care opportunities. Outgoing CEO Dawn Bitz said it had been a privilege to lead Adherium over the past year, expressing confidence in the company's future under Mr Perry's leadership and thanking employees, customers, partners and investors for their support during her tenure.

Incoming Interim CEO Background

John Perry currently serves as Adherium's Chief Commercial Officer and has been involved in the company's commercial expansion strategy. He brings more than two decades of healthcare leadership experience, including expertise in commercialisation, healthcare technology, value-based care models, enterprise partnerships and revenue growth. The board said his understanding of Adherium's operations, customers and strategic priorities, together with his experience across the US healthcare sector, positions him to lead the company through the transition period.

Mr Baran added that Mr Perry's commercial expertise, industry relationships and understanding of the opportunities ahead for the company would provide continuity and momentum as Adherium continues executing its strategy.

Incoming CEO Commentary and Strategic Priorities

In his own comments, John Perry said Adherium has built momentum over the past year and that his focus as Interim CEO will be on executing the company's commercial strategy, accelerating adoption of the Hailie platform, and building on the foundations established by Ms Bitz and the broader team. He referenced the company's iCARE study, conducted in partnership with Intermountain Health and CareCentra, as reinforcing the value of Adherium's technology and marking a step in its transition toward value-based care.

Company Background

Adherium describes itself as a global leader in digital respiratory management, with its Hailie Smartinhaler platform cleared by the FDA. The company's growth strategy spans connected respiratory care, Remote Patient Monitoring and Value Based Care initiatives, targeting the broader healthcare shift toward monitoring and managing chronic respiratory disease outside of traditional clinical settings.

The company's Hailie platform is designed to attach to inhaler devices used by patients managing asthma and chronic obstructive pulmonary disease, capturing data on medication usage that can be shared with clinicians and care teams. This data-driven approach underpins Adherium's positioning within Remote Patient Monitoring, a segment of healthcare technology that has attracted growing attention from providers and payers seeking to manage chronic disease outside of in-person clinical visits. The company has also pointed to Value Based Care arrangements, in which providers are compensated based on patient outcomes rather than the volume of services delivered, as a further avenue through which its technology can be positioned with US healthcare customers.

Timing of the Transition

The leadership change comes as Adherium continues to build on commercial developments referenced by the company over the preceding twelve months, including its work with Intermountain Health and CareCentra on the iCARE study. The board's characterisation of the past year as a period of significant commercial progress, combined with the decision to elevate an existing senior executive rather than conduct an external search, suggests an intention to maintain operational continuity through the transition period. Adherium has not indicated a specific timeframe for the interim arrangement or outlined next steps regarding a permanent CEO appointment in the announcement.

Conclusion

The transition from Dawn Bitz to Interim CEO John Perry represents a leadership change at a point where Adherium has been building out its Remote Patient Monitoring and Value Based Care initiatives around the Hailie Smartinhaler platform. With Mr Perry's background in commercial healthcare partnerships and his existing familiarity with the company's operations, the coming months are likely to provide an indication of how the transition affects the pace of Adherium's stated growth strategy, and whether the board moves toward a permanent leadership appointment or extends Mr Perry's interim tenure.